Objectives: This study aimed to evaluate the incidence of health insurance claims recording the cancer stage and TNM codes representing tumor extension size (T), lymph node metastasis (N), and distant metastasis (M) for patients diagnosed with cancer and to determine whether this extracted data could be applied to the new ICD-11 codes.
Design: A cross-sectional study design was used, with the units of analysis as individual outpatients. Two dependent variables were extraction feasibility of cancer stage and TNM metastasis information from each claim. Expressibility of the two variables in ICD-11 was descriptively analysed.
Setting And Participants: The study was conducted in South Korea and study participants were outpatients: lung cancer (LC) (46616), stomach cancer (SC) (50103) and colorectal cancer (CC) (54707). The data set consisted of the first health insurance claim of each patient visiting a hospital from 1 July to 31 December 2021.
Results: The absolute extraction success rates for cancer stage based on claims with cancer stage was 33.3%. The rates for stage for LC, SC and CC were 30.1%, 35.5% and 34.0%, respectively. The rate for TNM was 11.0%. The relative extraction success rates for stage compared with that for CC (the reference group) were lower for patients with LC (adjusted OR (aOR), 0.803; 95% CI 0.782 to 0.825; p<0.0001) but higher for SC (aOR 1.073; 95% CI 1.046 to 1.101; p<0.0001). The rates of TNM compared that for CC were 40.7% lower for LC (aOR, 0.593; 95% CI 0.569 to 0.617; p<0.0001) and 43.0% lower for SC (aOR 0.570; 95% CI 0.548 to 0.593; p<0.0001). There were limits to expressibility in ICD-11 regarding the detailed cancer stage and TNM metastasis codes.
Conclusion: Extracting cancer stage and TNM codes from health insurance claims were feasible, but expressibility in ICD-11 codes was limited. WHO may need to create specific cancer stage and TNM extension codes for ICD-11 due to the absence of current rules in ICD-11.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10895217 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2023-073952 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Surgical and Pathological Results Following Neoadjuvant Nivolumab and Platinum-Based Chemotherapy for Locally Advanced Resectable NSCLC: A Multicentre Real-World Series From England.
Clin Lung Cancer
December 2024
Department of Thoracic Surgery, Liverpool Heart and Lung Hospital, Liverpool, UK.
Background: To evaluate the real-world surgical and pathological outcomes following neoadjuvant nivolumab in combination with chemotherapy in a multicentre national cohort of patients.
Methods: Retrospective analysis on consecutive patients treated in three tertiary referral hospitals in UK with neoadjuvant chemotherapy and immunotherapy (nivolumab) for stage II-IIIB nonsmall cell lung cancer (March 2023-May 2024). Surgical and pathological outcomes were assessed.
Efficacy and safety of chemotherapy combined with iodine-125 seed brachytherapy for intermediate and advanced oncogenic driver gene-negative non-small cell lung cancer.
Brachytherapy
January 2025
Department of Radiology, The First Affiliated Hospital of University of Science and Technology of China (USTC), Division of life Sciences and Medicine, University of Science and Technology, Hefei, Anhui 230022, PR China. Electronic address:
Purpose: To compare the effectiveness and safety of CT-guided iodine-125 seed brachytherapy in conjunction with chemotherapy against chemotherapy alone for the management of intermediate and advanced non-small cell lung cancer (NSCLC) lacking oncogenic driving genes.
Methods And Materials: Retrospective analysis was conducted on clinical data from 128 patients diagnosed with intermediate and advanced non-small cell lung cancer who received iodine-125 combined with chemotherapy or chemotherapy alone due to the absence of oncogenic driver gene mutations. The patients in two groups were compared at 6-month follow-up for objective remission rate (ORR), Disease control rate (DCR), local progression-free survival (LPFS), overall survival (OS), clinical symptom improvement, and adverse events.
Clinical value of multi-slice spiral CT in evaluating preoperative TNN staging and postoperative recurrence and metastasis of colon carcinoma.
SLAS Technol
January 2025
Department of Radiology, Huzhou First People's Hospital, Huzhou 313000, Zhejiang Province, China. Electronic address:
To evaluate the clinical value of multi-slice spiral CT in preoperative TNN staging and postoperative recurrence and metastasis of colon carcinoma, and to provide evidence for the reliability of CT in the diagnosis of colon carcinoma METHODS: 89 patients with colon carcinoma diagnosed pathologically in our hospital from July 2020 to April 2023 were selected retrospectively. The preoperative TNN staging and postoperative recurrence and metastasis were monitored by 64 row 128 layer spiral CT. The diagnostic coincidence rate, TNM staging coincidence rate and postoperative recurrent TNM staging accuracy were evaluated according to the pathological diagnosis RESULTS: The diagnostic coincidence rate of multi-slice spiral CT was 97.
View Article and Find Full Text PDFTwo sides of the same coin-sexuality from the perspective of women diagnosed with breast cancer and their partners: A qualitative study.
Eur J Oncol Nurs
January 2025
Hacettepe University, Oncology Hospital, Ankara, Turkey. Electronic address:
Purpose: After the diagnosis of breast cancer, women's sexuality becomes complex, and the sexual lives of couples are strongly affected by the treatment process of the disease. The aim of this study is to determine the perceptions, experiences, expectations, and needs related to sexuality from the perspective of women diagnosed with breast cancer and their partners.
Method: In this study, a descriptive qualitative design based on a thematic analysis approach was used.
Can microbiota gut-brain axis reverse neurodegenerative disorders in human?
Ageing Res Rev
January 2025
Medical Science and Technology Innovation Center, Shandong Key Laboratory of Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, 440 Jiyan Road, Jinan, Shandong 250117, P R China; School of Medicine and Allied Health Sciences, University of The Gambia; Department of Medical Microbiology, Central South University Changsha, Hunan Provinces, China. Electronic address:
The trillions of microbial populations residing in the gut have recently shown that they can be used as a remedy for various diseases. The gut microbiota-brain-axis interface is one unique pathway that the microbiota demonstrates its medicinal value. This medicinal value is further seen when there is a decline in gut microbial diversity (dysbiosis).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!